Lunresertib is under clinical development by Repare Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lunresertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lunresertib overview
Repare Therapeutics overview
Repare Therapeutics is a precision oncology company that develops novel therapeutics targeting specific vulnerabilities of tumor cells. The company’s pipeline products include RP-3500 to treat genetically defined cancers, PKMYT1 Inhibitor RP-6306 and DNA Polymerase ? for repairing DNA breaks in homologous recombination deficient (HRD) cells. Repare’s proprietary SNIPRx, a genomic and chemo-genomic synthetic lethal screening platform combines CRISPR-enabled gene editing target discovery technology with high-resolution protein crystallography, computational biology, medicinal chemistry and clinical informatics to generate small molecules for clinical investigation. It operates offices in the US and Canada and a laboratory in Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.
For a complete picture of Lunresertib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.